Skip to main content Skip to navigation

Ramesh Arasaradnam

Professor Arasaradnam is a consultant Gastroenterologist and was former chair of the Research Committee of the British Society of Gastroenterology until 2021 before taking position as Academic Vice President at the Royal College of Physicians London.

His research interest is in colon cancer biomarker and diagnostic research, bile acid pathophysiology and artiificial intelligence where he leads on several NIHR studies. He has an interest in volatile organic compound (VOC) in cancer diagnosis and is part of an European VOC interest group.

He received an OBE as part of the Queen's birthday Honours in 2020 for his services to the NHS during COVID-19.

His clinical interest lies in GI physiology and development of small bowel Enteroscopy service at University Hospital Coventry & Warwickshire (UHCW).


Selected recent publications

Urine as a biological modality for colorectal cancer detection.

Chandrapalan S, Arasaradnam RP.

Expert Rev Mol Diagn. 2020 Mar 11:1-8. doi: 10.1080/14737159.2020.1738928. [Epub ahead of print]

Utility of volatile organic compounds as a diagnostic tool in preterm infants.

Wright H, Bannaga AS, Iriarte R, Mahmoud M, Arasaradnam RP.

Pediatr Res. 2020 Mar 2. doi: 10.1038/s41390-020-0828-3. [Epub ahead of print] Review.

Microbial imbalance in inflammatory bowel disease patients at different taxonomic levels.

Alam MT, Amos GCA, Murphy ARJ, Murch S, Wellington EMH, Arasaradnam RP.

Gut Pathog. 2020 Jan 4;12:1. doi: 10.1186/s13099-019-0341-6. eCollection 2020.

Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug.

Keller JJ, Vehreschild MJ, Hvas CL, Jørgensen SM, Kupciskas J, Link A, Mulder CJ, Goldenberg SD, Arasaradnam R, Sokol H, Gasbarrini A, Hoegenauer C, Terveer EM, Kuijper EJ, Arkkila P; UEG working group of the Standards and Guidelines initiative Stool banking for FMT.

United European Gastroenterol J. 2019 Dec;7(10):1408-1410. doi: 10.1177/2050640619887579. Epub 2019 Nov 14.

Diagnosing Inflammatory bowel disease using noninvasive applications of volatile organic compounds: a systematic review.

Bannaga AS, Farrugia A, Arasaradnam RP.

Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1113-1122. doi: 10.1080/17474124.2019.1685873. Epub 2019 Nov 8.

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.

UNIFI Study Group.

N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750.

Breath analysis using eNose technology to diagnose inflammatory bowel disease - early results.

Tiele A, Wicaksono A, Kansara J, Arasaradnam R, Covington J.

Future Healthc J. 2019 Mar;6(Suppl 1):79. doi: 10.7861/futurehosp.6-1-s79.

Systematic review with meta-analysis of over 90 000 patients. Does fast-track review diagnose colorectal cancer earlier?

Mozdiak E, Weldeselassie Y, McFarlane M, Tabuso M, Widlak MM, Dunlop A, Tsertsvadze A, Arasaradnam RP.

Aliment Pharmacol Ther. 2019 Aug;50(4):348-372. doi: 10.1111/apt.15378. Epub 2019 Jul 8. Review.

Urinary volatile organic compounds and faecal microbiome profiles in colorectal cancer.

McFarlane M, Millard A, Hall H, Savage R, Constantinidou C, Arasaradnam R, Nwokolo C.

Colorectal Dis. 2019 Nov;21(11):1259-1269. doi: 10.1111/codi.14739. Epub 2019 Jul 10.

Fibroblast growth factor 7 signalling is disrupted in colorectal cancer and is a potential marker of field cancerisation.

Patel A, Tripathi G, McTernan P, Gopalakrishnan K, Ali O, Spector E, Williams N, Arasaradnam RP.

J Gastrointest Oncol. 2019 Jun;10(3):429-436. doi: 10.21037/jgo.2019.02.11.

Enterosgel for the treatment of adults with acute diarrhoea in a primary care setting: a randomised controlled trial.

Howell CA, Markaryan E, Allgar V, Kemppinen A, Khovanov A, Pandya P, Arasaradnam R.

BMJ Open Gastroenterol. 2019 Apr 15;6(1):e000287. doi: 10.1136/bmjgast-2019-000287. eCollection 2019.

Letter: improving detection of colorectal cancer using two-stage investigation process-faecal immunochemical test and urinary volatile organic compounds.

Widlak MM, Neal M, Arasaradnam RP.

Aliment Pharmacol Ther. 2019 Jun;49(11):1459-1460. doi: 10.1111/apt.15278. No abstract available.

Breath Analysis Using eNose and Ion Mobility Technology to Diagnose Inflammatory Bowel Disease-A Pilot Study.

Tiele A, Wicaksono A, Kansara J, Arasaradnam RP, Covington JA.

Biosensors (Basel). 2019 Apr 12;9(2). pii: E55. doi: 10.3390/bios9020055.

Colorectal cancer and adenoma screening using urinary volatile organic compound (VOC) detection: early results from a single-centre bowel screening population (UK BCSP).

Mozdiak E, Wicaksono AN, Covington JA, Arasaradnam RP.

Tech Coloproctol. 2019 Apr;23(4):343-351. doi: 10.1007/s10151-019-01963-6. Epub 2019 Apr 15.

The role of fecal markers in the investigation of patients with chronic diarrhea.

Chandrapalan S, Arasaradnam RP.

Pol Arch Intern Med. 2019 Jun 28;129(6):408-413. doi: 10.20452/pamw.14787. Epub 2019 Apr 4.

Guidelines for the investigation of chronic diarrhoea in adults: British Society of Gastroenterology, 3rd edition.

Arasaradnam RP, Brown S, Forbes A, Fox MR, Hungin P, Kelman L, Major G, O'Connor M, Sanders DS, Sinha R, Smith SC, Thomas P, Walters JRF.

Gut. 2018 Aug;67(8):1380-1399. doi: 10.1136/gutjnl-2017-315909. Epub 2018 Apr 13.

Book Chapters

Arasaradnam & Bardhan. Cancer Treatment and Prevention; Francis Taylor 2010

Arasaradnam & Nwokolo. Ulcerative Colitis - Molecular determinants of pathogenesis of UC; Impegna 2011


'A Diagnostic Device'; PCT/GB2011/052063

'Bile Acid Diarrhoea'; 1316188.0



Job Title
Associate Professor
Warwick Medical School